New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

AI Briefing

• – New data from the HELIOS-B Phase 3 study supports vutrisiran as a first-line treatment option for ATTR-CM, demonstrating robust and consistent clinical benefit across various patient populations.
• – These results build on the growing body of evidence for vutrisiran's efficacy and safety profile, reinforcing the treatment's durability of TTR knockdown.
• – Alnylam Pharmaceuticals' vutrisiran is now poised to become a leading treatment option for patients with ATTR-CM.